Tenax Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-8.7%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$1.45next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release & Corporate Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
LEVEL Phase 3 Trial Randomization Status Quarterly230.0Target: 230 (Fully Randomized)
Cash and Cash Equivalents Quarterly118.8MTarget: Sufficient to fund operations through Q1 2028
LEVEL-2 Phase 3 Trial Enrollment Target QuarterlyTarget: 540 patients randomized 2:1
Watch Items
- Topline data release from the Phase 3 LEVEL study of TNX-103 in PH-HFpEFTrigger: Q3 2026Action: Evaluate clinical efficacy (6MWD change at Week 12) and safety profile to determine regulatory filing viability.
- Enrollment progress of the global Phase 3 LEVEL-2 trialTrigger: Completion of enrollment by end of 2027Action: Monitor site activation and patient recruitment rates globally to ensure timeline adherence.
- Cash burn rate and runway extensionTrigger: Runway falling below 12 monthsAction: Assess strategic financing options, non-dilutive funding, or partnerships to support commercialization prep.
Research as of 19 Jun 2026